Printed from Voxsanity (voxsanity.com.au) — NCT07609251 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Lung Cancer
Phase 2 Lung Cancer Trial, Not Yet Recruiting
NCT07609251
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who are willing and able to sign a consent form agreeing to take part in the study.
- People with a performance status rating of 0 or 1 on the ECOG scale, meaning they are fully active or have only minor limitations in physical activity (confirm with trial site).
- People with an expected survival of more than 3 months.
- People who have been confirmed by tissue or cell testing to have locally advanced (Stage IIIB or IIIC) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) that cannot be fully removed by surgery and is not suitable for curative radiation combined with chemotherapy.
- People without certain genetic alterations (AGA) who have had their cancer worsen during or after treatment with immune checkpoint therapy (PD-(L)1 inhibitors) and chemotherapy; or people with certain genetic alterations (AGA) who have already received appropriate targeted treatment, and if EGFR-positive, have also previously been treated with specific combination therapies or antibody-drug treatments (confirm with trial site).
- People who have at least one measurable tumour site outside the brain, as defined by standard measurement criteria (RECIST v1.1).
- People whose major organs (such as liver, kidneys, and bone marrow) are functioning well enough to meet the trial's requirements.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose cancer has been confirmed by tissue or cell testing to contain small cell carcinoma components.
- People who have previously been treated with the chemotherapy drug docetaxel.
- People who currently have symptoms caused by cancer that has spread to the brain or central nervous system.
- People who received their last cancer treatment within 4 weeks before the first dose of the study drug.
- People whose scans at screening show the tumour is growing into major blood vessels or nearby vital organs, or where there is a risk of an abnormal connection forming between the oesophagus and the airway or chest cavity, and the investigator considers this unsuitable for enrolment.
- People who have a history of severe high blood pressure crises or high blood pressure affecting the brain, or whose blood pressure cannot be controlled with medication.
- People who have an active autoimmune disease, or a history of autoimmune disease that may be likely to return.
- People who have a tendency to bleed, a high risk of bleeding, or a disorder affecting blood clotting.
- People who have been diagnosed with another type of cancer.
- People who have a severe or active infection, active tuberculosis, a positive HIV test, active hepatitis B or C, or known active syphilis at the time of starting the study.
- People who have uncontrolled fluid build-up around the lungs, heart, or abdomen that needs to be drained repeatedly.
- People who have a history of lung inflammation (not caused by infection) that required steroid treatment, or who currently have a chronic lung condition called interstitial lung disease.
- People who have previously received a transplant of an organ or blood stem cells from another person.
- People who are known to be allergic to any ingredient in the study drug, to a class of chemotherapy drugs called taxanes, or who have had a severe allergic reaction to any monoclonal antibody treatment.
- People who are pregnant or currently breastfeeding.
- People whom the investigator considers unsuitable for the trial for any other reason.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Sinocelltech Ltd.
Registry
ClinicalTrials.gov
Start date
1 May 2026
Est. completion
1 October 2028
Where this trial is recruiting
🇨🇳 China
Primary endpoints
Frequency of adverse events (AEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 29 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.